Trial · NCT03568708
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine | Change in bone mineral density and body composition from baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | Z-score | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) at the Whole Body Less Head, Total Hip, and Femoral Neck | baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | Z-score | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Volumetric Bone Mineral Density (vBMD) at the Distal Radius as Measured by Peripheral Quantitative Computed Tomography (pQCT) | Change from baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | mg/mm^3 | LEAST_SQUARES_MEAN |
| SECONDARY | Anthropometrics | Baseline and 24 months | kg/m^2 | MEAN | |
| SECONDARY | Change in Lean Mass as Measured by DXA Body Composition | Change in lean mass from baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Symptoms of Anxiety as Measured by Screen for Child Anxiety Related Disorders (SCARED) | Change from SCARED score baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Symptoms of Depression as Measured by Child Depression Inventory-II (CDI-II) | Change from CDI-II score from baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | T-score | LEAST_SQUARES_MEAN |
| SECONDARY | Change in Memory as Assessed by the Children and Adolescent Memory Profile (CHAMP) Total Memory Index Score | Change from score from baseline to 24 months | score on a scale | LEAST_SQUARES_MEAN | |
| SECONDARY | Change in Quality of Life as Assessed by the Child Health Questionnaire-Child Self-Report Form (CHQ-CF87) | Change from baseline to 24 months | One POI participant had prior oral contraceptive exposure, no matched control, and did not follow up for subsequent visits. For these reasons it was recommended that her data not be included in the analyses. | score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Compliance With Transdermal Estrogen Patch | Patch Calendars were collected at 6 months, 12 months, 18 months and 24 months. Data presented is through study completion. | As only participants with POI were prescribed TDE2 patches, we only report data on this cohort. | percentage of weeks with TDE2 use | MEAN |
| SECONDARY | Study Medications - Serum Estradiol | Baseline, 12 months, 24 months | The study was originally designed as a 12 month longitudinal trial. Subjects were given the option to continue for 24 months. One case participant declined the extension. As only participants with POI were prescribed transdermal estradiol patches, we only report data on this cohort. | pg/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03568708/outcomes